Hemlibra Found Effective for Severe Hemophilia A in Clinical Setting

Hemlibra Found Effective for Severe Hemophilia A in Clinical Setting

293416

Hemlibra Found Effective for Severe Hemophilia A in Clinical Setting

Preventive, or prophylactic, treatment with Hemlibra (emicizumab) safely and effectively managed bleeding in adults and children with severe hemophilia A, a real-world study has found. The study, “Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring,” was published in the journal Haemophilia. Originally developed by Roche’s subsidiary Chugai Pharmaceutical and now marketed by Genentech, Hemlibra is a bispecific antibody — a protein that is able to bind to two targets at the same time — that is…

You must be logged in to read/download the full post.